Celecoxib compared with sustained-release paracetamol for osteoarthritis: A series of n-of-1 trials

M. J. Yelland, C. J. Nikles, N. McNairn, C. B. Del Mar, P. J. Schluter, R. M. Brown

Research output: Contribution to journalArticleResearchpeer-review

44 Citations (Scopus)
33 Downloads (Pure)

Abstract

Objective. To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients. Methods. Evaluation of community-based patients undergoing n-of-1 trials which consisted of double-blind, crossover comparisons of celecoxib 200 or 400 mg/day with sustained-release paracetamol 1330 mg three times a day in three pairs of 2 week treatment periods per drug with random order of the drugs within pairs. Outcomes evaluated were pain and stiffness in sites nominated by the patient, functional limitation scores, preferred medication, side effects and changes in drug use after an n-of-1 trial. Participants were 59 patients with osteoarthritis in multiple sites (hip 6, knee 24, hand 6, shoulder/neck 8, back 14, foot 5), with pain for ≥1 month severe enough to warrant consideration of long-term use of celecoxib but for whom there was doubt about its efficacy. Forty-one n-of-1 trials were completed. Results. Although on average, celecoxib showed better scores than SR paracetamol [0.2 (0.1) for pain, 0.3 (0.1) for stiffness and 0.3 (0.1) for functional limitation], 33 of the 41 individual patients (80%) failed to identify the differences between SR paracetamol and celecoxib in terms of overall symptom relief. Of the eight patients who were able to identify the differences, seven had better relief with celecoxib and one with SR paracetamol. In 25 out of 41 [61%] patients, subsequent management was consistent with their trial results. Conclusions. N-of-1trials may provide a rational and effective method to best choose drugs for individuals with osteoarthritis. SR paracetamol is more useful than celecoxib for most patients of whom management is uncertain.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalRheumatology
Volume46
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Celecoxib
Acetaminophen
Osteoarthritis
Pharmaceutical Preparations
Pain

Cite this

Yelland, M. J. ; Nikles, C. J. ; McNairn, N. ; Del Mar, C. B. ; Schluter, P. J. ; Brown, R. M. / Celecoxib compared with sustained-release paracetamol for osteoarthritis : A series of n-of-1 trials. In: Rheumatology. 2007 ; Vol. 46, No. 1. pp. 135-140.
@article{af3e03eedbef43a292be663d116b472d,
title = "Celecoxib compared with sustained-release paracetamol for osteoarthritis: A series of n-of-1 trials",
abstract = "Objective. To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients. Methods. Evaluation of community-based patients undergoing n-of-1 trials which consisted of double-blind, crossover comparisons of celecoxib 200 or 400 mg/day with sustained-release paracetamol 1330 mg three times a day in three pairs of 2 week treatment periods per drug with random order of the drugs within pairs. Outcomes evaluated were pain and stiffness in sites nominated by the patient, functional limitation scores, preferred medication, side effects and changes in drug use after an n-of-1 trial. Participants were 59 patients with osteoarthritis in multiple sites (hip 6, knee 24, hand 6, shoulder/neck 8, back 14, foot 5), with pain for ≥1 month severe enough to warrant consideration of long-term use of celecoxib but for whom there was doubt about its efficacy. Forty-one n-of-1 trials were completed. Results. Although on average, celecoxib showed better scores than SR paracetamol [0.2 (0.1) for pain, 0.3 (0.1) for stiffness and 0.3 (0.1) for functional limitation], 33 of the 41 individual patients (80{\%}) failed to identify the differences between SR paracetamol and celecoxib in terms of overall symptom relief. Of the eight patients who were able to identify the differences, seven had better relief with celecoxib and one with SR paracetamol. In 25 out of 41 [61{\%}] patients, subsequent management was consistent with their trial results. Conclusions. N-of-1trials may provide a rational and effective method to best choose drugs for individuals with osteoarthritis. SR paracetamol is more useful than celecoxib for most patients of whom management is uncertain.",
author = "Yelland, {M. J.} and Nikles, {C. J.} and N. McNairn and {Del Mar}, {C. B.} and Schluter, {P. J.} and Brown, {R. M.}",
year = "2007",
month = "1",
doi = "10.1093/rheumatology/kel195",
language = "English",
volume = "46",
pages = "135--140",
journal = "British Journal of Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

Celecoxib compared with sustained-release paracetamol for osteoarthritis : A series of n-of-1 trials. / Yelland, M. J.; Nikles, C. J.; McNairn, N.; Del Mar, C. B.; Schluter, P. J.; Brown, R. M.

In: Rheumatology, Vol. 46, No. 1, 01.2007, p. 135-140.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Celecoxib compared with sustained-release paracetamol for osteoarthritis

T2 - A series of n-of-1 trials

AU - Yelland, M. J.

AU - Nikles, C. J.

AU - McNairn, N.

AU - Del Mar, C. B.

AU - Schluter, P. J.

AU - Brown, R. M.

PY - 2007/1

Y1 - 2007/1

N2 - Objective. To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients. Methods. Evaluation of community-based patients undergoing n-of-1 trials which consisted of double-blind, crossover comparisons of celecoxib 200 or 400 mg/day with sustained-release paracetamol 1330 mg three times a day in three pairs of 2 week treatment periods per drug with random order of the drugs within pairs. Outcomes evaluated were pain and stiffness in sites nominated by the patient, functional limitation scores, preferred medication, side effects and changes in drug use after an n-of-1 trial. Participants were 59 patients with osteoarthritis in multiple sites (hip 6, knee 24, hand 6, shoulder/neck 8, back 14, foot 5), with pain for ≥1 month severe enough to warrant consideration of long-term use of celecoxib but for whom there was doubt about its efficacy. Forty-one n-of-1 trials were completed. Results. Although on average, celecoxib showed better scores than SR paracetamol [0.2 (0.1) for pain, 0.3 (0.1) for stiffness and 0.3 (0.1) for functional limitation], 33 of the 41 individual patients (80%) failed to identify the differences between SR paracetamol and celecoxib in terms of overall symptom relief. Of the eight patients who were able to identify the differences, seven had better relief with celecoxib and one with SR paracetamol. In 25 out of 41 [61%] patients, subsequent management was consistent with their trial results. Conclusions. N-of-1trials may provide a rational and effective method to best choose drugs for individuals with osteoarthritis. SR paracetamol is more useful than celecoxib for most patients of whom management is uncertain.

AB - Objective. To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients. Methods. Evaluation of community-based patients undergoing n-of-1 trials which consisted of double-blind, crossover comparisons of celecoxib 200 or 400 mg/day with sustained-release paracetamol 1330 mg three times a day in three pairs of 2 week treatment periods per drug with random order of the drugs within pairs. Outcomes evaluated were pain and stiffness in sites nominated by the patient, functional limitation scores, preferred medication, side effects and changes in drug use after an n-of-1 trial. Participants were 59 patients with osteoarthritis in multiple sites (hip 6, knee 24, hand 6, shoulder/neck 8, back 14, foot 5), with pain for ≥1 month severe enough to warrant consideration of long-term use of celecoxib but for whom there was doubt about its efficacy. Forty-one n-of-1 trials were completed. Results. Although on average, celecoxib showed better scores than SR paracetamol [0.2 (0.1) for pain, 0.3 (0.1) for stiffness and 0.3 (0.1) for functional limitation], 33 of the 41 individual patients (80%) failed to identify the differences between SR paracetamol and celecoxib in terms of overall symptom relief. Of the eight patients who were able to identify the differences, seven had better relief with celecoxib and one with SR paracetamol. In 25 out of 41 [61%] patients, subsequent management was consistent with their trial results. Conclusions. N-of-1trials may provide a rational and effective method to best choose drugs for individuals with osteoarthritis. SR paracetamol is more useful than celecoxib for most patients of whom management is uncertain.

UR - http://www.scopus.com/inward/record.url?scp=33845585435&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kel195

DO - 10.1093/rheumatology/kel195

M3 - Article

VL - 46

SP - 135

EP - 140

JO - British Journal of Rheumatology

JF - British Journal of Rheumatology

SN - 1462-0324

IS - 1

ER -